Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

argenx: Clinical Trials & FDA Approval Profile

argenx (Global / Institutional) sponsors 54 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 29 active protocols (13 recruiting now), 17 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)14.8%
Median Closed Enrollment vs National (145 pts)103 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for argenx
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)54
Active Pipeline (Recruiting Now)29 (13)
Completed vs Stopped Early17 / 8 (14.8%)
Median Closed Actual Enrollment103 participants
Physical Hospital Site Disclosure99.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With argenx
Hospital Research SiteLocationShared Protocols
Hospital de La Santa Creu I Sant PauBarcelona9
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MD7
Fakultni nemocnice BrnoBrno, Moravia6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by argenx
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07287982A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in PediPhase IIRECRUITING
NCT06544499A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune ThrombocytopeniaPhase IIIRECRUITING
NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPPhase IIIRECRUITING
NCT07570316A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseasePhase IIIRECRUITING
NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the argenx Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI